Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?
| Image |  |
|---|---|
| Description | scientific article published on 01 October 2020 |
| Author/s | |
| Publication date | October 1, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |